Novo Nordisk, a leading Danish pharmaceutical firm, reported robust financial results for 2024, exceeding Wall Street projections with a 25% revenue increase to approximately $40.6 billion. However, the company anticipates a slowdown in sales growth for 2025 due to intensifying competition, notably from Eli Lilly. The stock has fallen about 40% since peaking in mid-2023, driven by concerns regarding demand for obesity drugs and mixed results from clinical trials. Analysts are wary as the market's growth expectations in excess of $100 billion face scrutiny amidst evolving political landscapes.
Novo Nordisk reported a profit and revenue in 2024 that exceeded Wall Street expectations, but anticipates slower sales growth due to rising competition in the obesity drug market.
Despite retaining its position as Europe's most valuable company, Novo Nordisk's stock price has dropped approximately 40 percent since last June due to concerns over demand for obesity drugs.
Collection
[
|
...
]